- Trials with a EudraCT protocol (191)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
191 result(s) found for: Skin Diseases AND Moderate and Severe Plaque Psoriasis AND Plaque Psoriasis.
Displaying page 10 of 10.
EudraCT Number: 2013-004918-18 | Sponsor Protocol Number: OPTIMAP | Start Date*: 2014-02-03 |
Sponsor Name:Academic Medical Center | ||
Full Title: Optimising adalimumab treatment in psoriasis with concomitant methotrexate. | ||
Medical condition: psoriasis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017272-24 | Sponsor Protocol Number: P05495 | Start Date*: 2011-01-10 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation | |||||||||||||
Full Title: Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous SCH 900222 in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) BE (Completed) GB (Completed) FI (Completed) AT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000215-92 | Sponsor Protocol Number: BYH1003 | Start Date*: 2019-07-02 | |||||||||||
Sponsor Name:Bay Pharma GmbH | |||||||||||||
Full Title: Prospective, randomized, double blinded, placebo controlled, multicentre study for the evaluation of efficacy and safety of a Tacrolimus-containing solution (TACRO-Skin) in subjects with mild to se... | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003600-23 | Sponsor Protocol Number: APRICOT | Start Date*: 2016-04-01 | |||||||||||
Sponsor Name:Guy's and St Thomas NHS Foundation Trust | |||||||||||||
Full Title: Treatment of Pustular Psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies | |||||||||||||
Medical condition: Acral Pustular Psoriasis, specifically but not limited to Palmo-Plantar Pustulosis will be the target population for therapeutic intervention with Anakinra in this study. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001671-79 | Sponsor Protocol Number: CAIN457ADE08 | Start Date*: 2018-02-15 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A randomized, multicenter 28 week study to compare the efficacy and safety of combining Cosentyx (Secukinumab) (4-weekly, 300 mg s.c.) with a lifestyle intervention to Cosentyx therapy alone in adu... | |||||||||||||
Medical condition: Moderate to severe plaque type psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001770-59 | Sponsor Protocol Number: BAT-2306-002-CR | Start Date*: 2022-10-19 | |||||||||||
Sponsor Name:Bio-Thera Solutions, Ltd. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2306 with Cosentyx® in Patients with Moderate to Severe Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003551-11 | Sponsor Protocol Number: TILD-19-12 | Start Date*: 2020-08-17 |
Sponsor Name:Sun Pharma Advanced Research Company Ltd. | ||
Full Title: A Multicenter, Randomized, Placebo and Active Comparator-Controlled Clinical trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects from 6 to <18 Years... | ||
Medical condition: moderate to severe chronic plaque psoriasis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: HU (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) SK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001918-42 | Sponsor Protocol Number: TDM-ADA2019 | Start Date*: 2020-04-22 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: A non-inferiority study on dose reduction of adalimumab in psoriasis patients who are overtreated. | |||||||||||||
Medical condition: Patients with moderate-to-severe psoriasis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005036-26 | Sponsor Protocol Number: FXT-05 | Start Date*: 2011-11-29 | ||||||||||||||||||||||||||
Sponsor Name:Funxional Therapeutics Ltd | ||||||||||||||||||||||||||||
Full Title: An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease | ||||||||||||||||||||||||||||
Medical condition: Asthma Chronic obstructive pulmonary disease Rheumatoid arthritis Psoriasis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004021-33 | Sponsor Protocol Number: ANB019-002 | Start Date*: 2018-05-04 | |||||||||||
Sponsor Name:AnaptysBio Inc. | |||||||||||||
Full Title: A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis | |||||||||||||
Medical condition: Generalized Pustular Psoriasis (GPP) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005122-11 | Sponsor Protocol Number: 069-008 | Start Date*: 2018-03-27 |
Sponsor Name:Prof. Dr. Kristian Reich | ||
Full Title: A multicenter, open label, single-arm pilot to evaluate the efficacy and safety of oral apremilast in patients with moderate to severe palmoplantar pustulosis (PPP) (APLANTUS) | ||
Medical condition: Palmoplantar pustulosis (PPP) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
